1 Department of Internal Medicine, Kerman University of Medical Sciences, Kerman, Iran

2 Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran


Sialadenitis is a rare adverse effect of captopril. We report a case of captopril‑induced 
sialadenitis in a patient with end‑stage renal disease (ESRD). A 20‑year‑old man with 
ESRD encountered parotid and submandibular swelling after receiving two doses of 
captopril, administered sublingually. Despite of prescribing dexamethasone, resuming 
hemodialysis, and discontinuing other drugs that also can cause parotitis, he improved 
later than what was reported in patients with normal renal function. In conclusion 
recovery from captopril‑induced sialadenitis in patients with ESRD may be more 
prolonged than that of patients with normal renal function; moreover, early hemodialysis 
which helps in drug removal may be the most effective treatment.


1. Krishnamurthy S, Vasudeva SB, Vijayasarathy S. Salivary 
gland disorders: A comprehensive review. World J Stomatol 
2015;4: 56-71.
2. Brooks KG, Thompson DF. A review and assessment of 
drug‑induced parotitis. Ann Pharmacother 2012;46:1688‑99.
3. Gislon Da Silva RM. Captopril‑induced bilateral parotid and 
submandibular sialadenitis. Eur J Clin Pharmacol 2004;60:449‑53.
4. Chauhan V, Negi RC, Sharma A, Gupta S, Mokta J, Verma B,et al. Enalaprilat induced acute parotitis. J Assoc Physicians 
India 2008;56:128‑9.
5. Moss JR, Zanation AM, Shores CG. ACE inhibitor associated 
recurrent intermittent parotid gland swelling. Otolaryngol 
Head Neck Surg 2005;133:992‑4.
6. Atkinson W, Wolfe S, Hamborsky J. Centers for Disease 
Control and Prevention Epidemiology and Prevention of 
Vaccine‑Preventable Diseases, “Pink Book,”. Washington, DC: 
Public Health Foundation; 2011.
7. Gültuna S, Usküdar O, Yüksel I, Basar O, Köklü S. Transient 
parotitis after conscious sedation for endoscopy. Endoscopy 
2009;41 Suppl 2:E53.
8. Kenningham J. An unusual case of postoperative facial 
swelling. Anaesthesia 2000;55:601‑2.
9. Suki WN, Massry SG. Therapy of Renal Diseases and Related 
Disorders. Boston: Kluwer Academic Publishers; 1991.
10. Drummer OH, Workman BS, Miach PJ, Jarrott B, Louis WJ. 
The pharmacokinetics of captopril and captopril disulfide 
conjugates in uraemic patients on maintenance dialysis: 
Comparison with patients with normal renal function. Eur J 
Clin Pharmacol 1987;32:267‑71.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, 
et al. A method for estimating the probability of adverse drug 
reactions. Clin Pharmacol Ther 1981;30:239‑45.